Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $33.40

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $33.40.

A number of research firms have recently commented on PCRX. Wall Street Zen upgraded Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Truist Financial raised Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a report on Friday, July 25th. Finally, Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Marcelo Bigal sold 4,912 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $23.67, for a total transaction of $116,267.04. Following the transaction, the director directly owned 11,393 shares of the company’s stock, valued at $269,672.31. This trade represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Several institutional investors have recently bought and sold shares of PCRX. Allspring Global Investments Holdings LLC acquired a new position in shares of Pacira BioSciences during the first quarter valued at approximately $277,000. ProShare Advisors LLC raised its stake in Pacira BioSciences by 30.2% in the 4th quarter. ProShare Advisors LLC now owns 16,003 shares of the company’s stock valued at $301,000 after purchasing an additional 3,710 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Pacira BioSciences by 112.8% in the 1st quarter. GAMMA Investing LLC now owns 3,694 shares of the company’s stock valued at $92,000 after purchasing an additional 1,958 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after purchasing an additional 794 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in Pacira BioSciences by 21,458.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 91,192 shares of the company’s stock worth $1,718,000 after purchasing an additional 90,769 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $24.58 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -8.84 and a beta of 0.40. The company has a 50 day moving average price of $25.23 and a 200-day moving average price of $24.87. Pacira BioSciences has a 1-year low of $15.16 and a 1-year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The firm had revenue of $181.10 million for the quarter, compared to the consensus estimate of $183.11 million. During the same period in the prior year, the firm posted $0.96 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. Pacira BioSciences has set its FY 2025 guidance at EPS. Equities research analysts forecast that Pacira BioSciences will post 2.41 EPS for the current year.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.